Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Pressure BioSciences, Inc.    PBIO   US74112E1091

SummaryNewsCalendarCompanyFinancialsForum 

Pressure Biosciences : Pressure BioSciences, Inc. to Present at the NY Arch Investment Conference

10/13/2006| 08:00am US/Eastern
Recommend:
0

Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that it will present at the Arch Investment Conference to be held at The St. Regis Hotel, Iridium Room (lower level), 55th Street and 5th Avenue, New York, NY, on Tuesday, October 17, 2006. Mr. Edward H. Myles, PBI Vice President of Finance and CFO, will give a corporate overview at 9:00 am.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2006, in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com


© Business Wire 2006
Recommend :
0
Partner Area
React to this article
 
Latest news on PRESSURE BIOSCIENCES, INC.
2d ago PRESSURE BIOSCIENCES, INC.: Breakthrough Method for Lipid Analysis in Fecal Mat..
03/19 PRESSURE BIOSCIENCES, INC.: New Applications of Pressure BioSciences’ PCT Platf..
2012 PRESSURE BIOSCIENCES, INC.: Appoints Conrad F. Mir as Chief Financial Officer
2012 PRESSURE BIOSCIENCES, INC.: Pressure BioSciences Partners with Constant Systems..
2012 PRESSURE BIOSCIENCES, INC.: Reports Record PCT Product Sales in Q3 2012
2012 PRESSURE BIOSCIENCES, INC.: Reports 69% Revenue Increase for Q1 2012
2012 PRESSURE BIOSCIENCES, INC.: and LEAP Technologies, Inc. Announce Co-Development..
2012 PRESSURE BIOSCIENCES, INC.: and Target Discovery, Inc. Expand Strategic License..
2012 PRESSURE BIOSCIENCES, INC.: Ironridge BioPharma to Invest $500,000 in Pressure ..
2012 PRESSURE BIOSCIENCES, INC.: Pressure BioSciences Common Stock to Begin Trading ..
Advertisement
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.